Clinical Trial Update: Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The "UP" Study [Phase 2]

View source ↗

Summary

Phase 2 trial of ursodeoxycholic acid (UDCA) for Parkinson's disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Ursodeoxycholic acid (ursodeoxycholic acid)

Snippet

Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED